Hemodynamic effects of bosentan in patients with chronic heart failure

Heart Failure Reviews

Volumn 6, Issue 4, 2001, Pages 325-334

  Kiowski, W ^a   Sutsch G ^a   Oechslin, E ^a   Bertel, O ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Antagonists; Bosentan; Endothelin 1; Heart failure; Hemodynamic effects; Hormones; Receptors

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEMODYNAMICS; HUMAN; LONG TERM CARE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SHORT COURSE THERAPY;

CHRONIC DISEASE; CLINICAL TRIALS; ENDOTHELIN-1; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0034897933     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011460426786     Document Type: Review

References (49)

1. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure
2. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
3. Role of neuroendocrine mechanisms in the pathogenesis of heart failure
4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators
5. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators
6. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
7. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials
8. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group
9. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF)
10. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial
11. Regulatory functions of the endothelium
12. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
13. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
14. The role of endothelin-1 in cardiovascular physiology and pathophysiology
15. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation
16. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure
17. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction
18. Endothelin in human congestive heart failure
19. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist
20. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
21. Cloning and characterization of cDNA encoding human A-type endothelin receptor
22. Cloning and sequence analysis of a cDNA encoding human nonselective type of endothelin receptor
23. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo
24. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels
25. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
26. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation
27. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor
28. Endothelin-1 stimulation of aldosterone and zona glomerulosa ouabainsensitive sodium/potassium-ATPase
29. Comparison of the signaling mechanisms involved in the ETB receptor-mediated secretagogue action of endothelin-1 on dispersed zona glomerulosa cells and capsule-zona glomerulosa preparations of the rat adrenal gland
30. Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex
31. Role of endothelin receptor subtypes in the in vivo regulation of renal function
32. SB 234551, a novel endothelin - A receptor antagonist, unmasks endothelin-induced renal vasodilatation in the dog
33. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure
34. Effects of endothelins on collagen turnover in cardiac fibroblasts
35. Endothelin receptors in cultured adult rat cardiac fibroblasts
36. Clearance of circulating endothelin-1 by ETB receptors in rats
37. ETB-mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells
38. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors
39. Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: Differential effects of acute and chronic ETA receptor blockade
40. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
41. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure
42. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators
43. Elevated endothelin-1 in heart failure and loss of normal response to postural change
44. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans
45. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
46. Impact of medical therapy on pulmonary hypertension in patients with congestive heart failure awaiting cardiac transplantation
47. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins
48. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
49. Multicenter, double-blind, placebo-controlled study of long-term endothelinblockade with bosentan in chronic heart failure - Results of the REACH-1 trial